Sarepta Therapeutics (SRPT) saw its shares increase by approximately 6% on Tuesday following the U.S. Department of Health and Human Services' (HHS) decision to include Duchenne muscular dystrophy (DMD) and metachromatic leukodystrophy in its newborn screening recommendations. These conditions typically manifest significant muscle deterioration or functional decline in children around four or five years old. The HHS aims to reduce diagnostic delays and the associated financial and emotional burden on families. Sarepta, along with Dyne Therapeutics and Wave Life Sciences, is developing treatments for DMD.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.